Literature DB >> 1354086

The effects of beta blockade with (epanolol) and without (atenolol) intrinsic sympathomimetic activity in stable angina pectoris. The Visacor Study Group.

J Boberg1, F F Larsen, S K Pehrsson.   

Abstract

Beta blockade constitutes efficient therapy for stable angina pectoris. The effects of lowering blood pressure and heart rate with such treatment are not always desired. Epanolol is a beta 1-selective partial agonist with minor effects on blood pressure and heart rate at rest. Atenolol is a pure beta 1-selective antagonist with more pronounced effects on blood pressure and heart rate at rest. The effects of epanolol, 200 mg o.d., and atenolol, 100 mg o.d., were compared in 173 middle-aged patients with stable angina pectoris in a randomized, double-blind, parallel group-controlled study for one year. No significant differences were shown in angina attack rate, nitrate consumption, or exercise performance. Resting heart rate and blood pressure were significantly lower on atenolol. Epanolol tended to be better tolerated than atenolol, as shown by visual analogue scales of well-being, activity, energy, and warm extremities, further supported by fewer reports on possible adverse reactions. In conclusion, epanolol appears to be as effective as atenolol and better tolerated in patients with stable angina pectoris.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1354086     DOI: 10.1002/clc.4960150808

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  2 in total

1.  Effective management of stable angina.

Authors:  M Petticrew; M Sculpher; J Kelland; R Elliott; D Holdright; M Buxton
Journal:  Qual Health Care       Date:  1998-06

2.  Absence of beneficial effect of intravenous metoprolol given during angioplasty in patients with single-vessel coronary artery disease.

Authors:  J W de Jong; J J Bonnier; T Huizer; R Ciampricotti; J R Roelandt
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.